? Tobacco and Environmental Carcinogenesis (TEC) Program The Tobacco and Environmental Carcinogenesis (TEC) Program, which received a ranking of ?Exceptional? merit in the 2015 CCSG submission, includes 17 members from six departments within the Perelman School of Medicine (Psychiatry, Medicine, Systems Pharmacology and Translational Therapeutics, Dermatology, Pediatrics, and Neuroscience) and from the School of Nursing and the Annenberg School of Communication, who elucidate how exposure to tobacco and environmental carcinogens cause cancer and how these exposures can be mitigated by risk reduction, intervention, and communication-based intervention strategies. The TEC Program is particularly focused on tobacco-related cancers, asbestos exposure and mesothelioma, and has a new effort in UV/light exposure and skin cancer. These research areas provide rich opportunities for inter- and intra-Programmatic research. TEC Program Leaders are Dr. Trevor Penning, an expert in environmental carcinogenesis, and Dr. Robert Schnoll, a leader in tobacco control, who together champion a translational and transdisciplinary vision for TEC. The scientific aims of the Program are to: 1) elucidate the pathways underlying exposure risk (e.g., risk factors for tobacco dependence; risk of environmental exposures for mesothelioma, lung cancer and skin cancer); 2) identify the mechanisms linking exposure to disease; 3) evaluate methods for exposure and risk reduction (e.g., tobacco cessation treatments; asbestos remediation; UV light protection); and 4) test methods of risk communication (e.g., tobacco marketing, regulatory science). The Program has 13 R01-equivalents. Program members accrued 1,642 subjects to interventional treatment trials and 2,776 subjects to non-interventional trials. As one of the two Population Science Programs, TEC Program members collaborate within TEC and across the Cancer Control, Cancer Therapeutics, Tumor Biology, Radiobiology and Imaging (RBI), and Immunobiology Programs and engage in population and community-based research within the Abramson Cancer Center (ACC) catchment area. TEC also leads transformative educational experiences across Penn and the catchment area. Seminal contributions during the project period include illustrating the potential use of low-nicotine content cigarettes as a national regulatory mechanism to reduce smoking rates and identifying novel mechanisms by which petrogenic polycyclic aromatic hydrocarbons in the environment are metabolically activated. The intra- and inter-Programmatic environment is facilitated by mentoring, symposia, working groups, and pilot grants. TEC has $5M in cancer- related grants (direct), of which $2.6M is from NCI and $4.8M is peer-reviewed. Collaborative grants include an NCI U54 Tobacco Center of Regulatory Science (with Cancer Control), a P30 Center of Excellence in Environmental Toxicology (CEET; with Cancer Control), and a NIDA funded P30 PET Addiction Center of Excellence (PACE; with RBI). Members have authored 316 cancer-related publications (21% intra- Programmatic; 22% inter-Programmatic; 78% multi-Institutional) during the current period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088751
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Raposo-Ferreira, Talita M M; Brisson, Becky K; Durham, Amy C et al. (2018) Characteristics of the Epithelial-Mesenchymal Transition in Primary and Paired Metastatic Canine Mammary Carcinomas. Vet Pathol 55:622-633
Kasner, Margaret T; Mick, Rosemarie; Jeschke, Grace R et al. (2018) Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Invest New Drugs 36:657-666
Karakasheva, Tatiana A; Lin, Eric W; Tang, Qiaosi et al. (2018) IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment. Cancer Res 78:4957-4970
Huffman, Austin P; Richman, Lee P; Crisalli, Lisa et al. (2018) Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 24:594-599
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215

Showing the most recent 10 out of 1047 publications